Charles River Laboratories International, Inc. (NYSE:CRL) Receives $189.77 Average PT from Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have been assigned a consensus rating of “Reduce” from the sixteen research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and fifteen have given a hold rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $189.77.

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $190.00 to $170.00 in a report on Friday, March 21st. JPMorgan Chase & Co. reduced their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Barclays dropped their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 18th. Finally, Bank of America decreased their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO James C. Foster purchased 6,075 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc raised its stake in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the period. Optiver Holding B.V. purchased a new position in shares of Charles River Laboratories International in the fourth quarter worth about $37,000. GeoWealth Management LLC boosted its position in Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after buying an additional 190 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in Charles River Laboratories International in the 4th quarter worth approximately $48,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 2.9 %

CRL stock opened at $136.95 on Friday. The firm’s fifty day simple moving average is $162.49 and its two-hundred day simple moving average is $180.95. The stock has a market capitalization of $7.00 billion, a price-to-earnings ratio of 912.99, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International has a twelve month low of $132.99 and a twelve month high of $258.56.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same period in the prior year, the company posted $2.46 EPS. The firm’s revenue for the quarter was down 1.1% on a year-over-year basis. As a group, analysts anticipate that Charles River Laboratories International will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).